CRISPR Therapeutics AG (CRSP) Financial Statements (2025 and earlier)

Company Profile

Business Address BAARERSTRASSE 14
ZUG, CH-6300
State of Incorp.
Fiscal Year End December 31
Industry (SIC) 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

6/30/2025
MRQ
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments1,903,8261,693,6921,815,3182,379,1291,690,333943,771
Cash and cash equivalent298,257389,477211,885923,0311,168,620943,771
Short-term investments1,605,5691,304,2151,603,4331,456,098521,713 
Receivables 25,000200,000 30514499
Other undisclosed current assets8,30614,38637,70838,07926,14343,677
Total current assets:1,937,1321,908,0781,853,0262,417,5131,716,620987,547
Noncurrent Assets
Operating lease, right-of-use asset143,461153,993156,921174,46050,86541,502
Property, plant and equipment134,093151,945163,634137,57542,16031,330
Long-term investments and receivables  1,97353,130   
Long-term investments  1,97353,130   
Intangible assets, net (including goodwill)  1671125180235
Intangible assets, net (excluding goodwill)  1671125180235
Restricted cash and investments11,51911,59111,63516,91316,8485,041
Other noncurrent assets15,8291,9754,6405,2911,2931,097
Total noncurrent assets:304,902321,493390,031334,364111,34679,205
TOTAL ASSETS:2,242,0342,229,5712,243,0572,751,8771,827,9661,066,752
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities55,78183,482105,110106,54373,34936,707
Taxes payable72410,473583
Accounts payable14,70938,14727,42814,8169,0945,944
Accrued liabilities41,07245,33577,68291,00353,78230,180
Deferred revenue3,8454,105 1,0112,341960
Debt      8,489
Other liabilities 10,4175,141201717,20710,950
Other undisclosed current liabilities17,73916,06315,97712,15811,362 
Total current liabilities:87,782108,791121,107119,88394,25957,106
Noncurrent Liabilities
Long-term debt and lease obligation:    212,87250,06744,050
Liabilities, other than long-term debt222,172237,977246,47119,66219,40626,171
Deferred revenue12,32314,01212,32312,32311,77611,776
Other liabilities3,4449585,9697,3397,63014,395
Operating lease, liability206,405223,007228,179212,87250,06744,050
Total noncurrent liabilities:222,172237,977246,471232,53469,47370,221
Total liabilities:309,954346,768367,578352,417163,732127,327
Equity
Equity, attributable to parent1,932,0801,882,8031,875,4792,399,4601,664,234939,425
Common stock2,6982,4972,4412,3912,2771,847
Treasury stock, value(62)(62)(63)(63)(63)(63)
Additional paid in capital3,293,5562,878,1552,734,8382,598,1142,235,6791,162,345
Accumulated other comprehensive income (loss)1,8401,913(15,647)(5,067)(83)7
Accumulated deficit(1,365,952)(999,700)(846,090)(195,915)(573,576)(224,711)
Total equity:1,932,0801,882,8031,875,4792,399,4601,664,234939,425
TOTAL LIABILITIES AND EQUITY:2,242,0342,229,5712,243,0572,751,8771,827,9661,066,752

Income Statement (P&L) ($ in thousands)

6/30/2025
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Revenues37,314371,2061,198914,963719289,590
Sublease income 573137 5,253587525
Gross profit:37,314371,2061,198914,963719289,590
Operating expenses(503,880)(593,744)(674,359)(541,435)(355,154)(242,850)
Operating income (loss):(466,566)(222,538)(673,161)373,528(354,435)46,740
Nonoperating income103,90171,81622,6616,0036,37920,566
Other nonoperating income103,90171,81622,6616,0036,37926,033
Income (loss) from continuing operations before equity method investments, income taxes:(362,665)(150,722)(650,500)379,531(348,056)67,306
Loss from equity method investments      (5,467)
Other undisclosed income from continuing operations before income taxes      5,467
Income (loss) from continuing operations before income taxes:(362,665)(150,722)(650,500)379,531(348,056)67,306
Income tax expense (benefit)(3,587)(2,888)325(1,870)(809)(448)
Income (loss) from continuing operations:(366,252)(153,610)(650,175)377,661(348,865)66,858
Income (loss) before gain (loss) on sale of properties:377,661(348,865)66,858
Net income (loss) available to common stockholders, diluted:(366,252)(153,610)(650,175)377,661(348,865)66,858

Comprehensive Income ($ in thousands)

6/30/2025
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Net income (loss):(366,252)(153,610)(650,175)377,661(348,865)66,858
Comprehensive income (loss):(366,252)(153,610)(650,175)377,661(348,865)66,858
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(73)17,560(10,580)(4,984)(90)15
Comprehensive income (loss), net of tax, attributable to parent:(366,325)(136,050)(660,755)372,677(348,955)66,873

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: